Michael Weiss

Michael Sean Weiss is the founder of TG Therapeutics, Inc., founded in 1993, serving as Chairman, President & Chief Executive Officer.
Mr. Weiss was the founder of ACCESS Oncology, Inc., founded in 1999, serving as Chairman & Chief Executive Officer from 1999 to 2003.
Mr. Weiss was the founder of Opus Point Partners Management LLC (Investment Management), founded in 2009, serving as Partner.
Mr. Weiss is the founder of Cyprium Therapeutics, Inc., founded in 2017, serving as Director since 2017.
Mr. Weiss was the founder of Opus Point Partners LLC, founded in 2009, serving as Partner & Portfolio Manager from 2009 to 2019.
Current jobs include Executive Chairman at Mustang Bio, Inc. since 2017 (job start 2015), Director at Fortress Biotech, Inc. since 2013, Director at Helocyte, Inc., Director at Cellvation, Inc., and Director at Baergic Bio, Inc. Former jobs include Chairman & Chief Executive Officer at Keryx Biopharmaceuticals, Inc. from 2002 to 2009, Chairman at Paligent, Inc., Non-Executive Chairman at National Holdings Corp.
from 2011 to 2012, Chairman at National Holdings Corp.
from 2016 to 2018, Executive Chairman at IASO Pharma, Inc., Chairman at XTL Biopharmaceuticals Ltd., Chairman at Checkpoint Therapeutics, Inc. from 2016 to 2025, Co-Chairman at Origo Acquisition Corp.
from 2014 to 2016, Director at Healthcare Integrated Services, Inc., Director at Genta, Inc., Non-Executive Director at Avenue Therapeutics, Inc. from 2015 to 2019, Director at Caelum Biosciences, Inc., Lawyer at Cravath, Swaine & Moore LLP, and Trustee at Cancer Care, Inc. Education includes undergraduate studies at State University of New York at Albany and graduate studies at Columbia Law School.